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Abstract
Fibrocytes are circulating, hematopoietic cells that express CD45 and Col1a1. They contribute to
wound healing and several fibrosing disorders by mechanisms that are poorly understood. In this
report, we demonstrate that fibrocytes predispose the lung to B16-F10 metastasis by recruiting
Ly-6C+ monocytes. To do so, we isolated fibrocytes expressing CD45, CD11b, CD13, and Col1a1
from the lungs of wild type (WT) and Ccr5−/− mice. WT but not Ccr5−/− fibrocytes increased the
number of metastatic foci when injected into Ccr5−/− mice (73 ± 2 versus 32 ± 5; p < 0.001). This
process was MMP9 dependent. Injection of WT enhanced GFP+ fibrocytes also increased the
number of Gr-1Int, CD11b+, and enhanced GFP− monocytes. Like premetastatic-niche monocytes,
these recruited cells expressed Ly-6C, CD117, and CD45. The transfer of these cells into Ccr5−/−
mice enhanced metastasis (90 ± 8 foci) compared with B cells (27 ± 2), immature dendritic cells
(31 ± 6), or alveolar macrophages (28 ± 3; p < 0.05). WT and Ccl2−/− fibrocytes also stimulated
Ccl2 expression in the lung by 2.07 ± 0.05- and 2.78 ± 0.36-fold compared with Ccr5−/− fibrocytes
(1.0 ± 0.06; p < 0.05). Furthermore, WT fibrocytes did not increase Ly-6C+ monocytes in Ccr2−/−
mice and did not promote metastasis in either Ccr2−/− or Ccl2−/− mice. These data support our
hypothesis that fibrocytes contribute to premetastatic conditioning by recruiting Ly-6C+
monocytes in a chemokine-dependent process. This work links metastatic risk to conditions that
mobilize fibrocytes, such as inflammation and wound repair.
Since their discovery in 1994, fibrocytes have been described as circulating, COL1A1-
expressing, hematopoietic cells (1). Derived from CD14 monocytes (2), these cells
constitute <1% of the adult leukocyte pool. In health, fibrocytes are thought to promote
wound healing by migrating into areas of injury and differentiating into activated fibroblasts
(3). This mechanism has also been inferred from observations of several fibrosing disorders,
including keloid formation (4), posttransplant bronchiolitis obliterans (5, 6), peritoneal
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fibrosis, and thyroid ophthalmopathy (7). However, there is little data to substantiate this
model in vivo.
A role for fibrocytes in tumor promotion has been more difficult to discern. A small number
of studies have focused on the ability of fibrocytes to propagate tumor stroma. This stroma
is populated with activated fibroblasts, which are characterized by their expression of α
smooth muscle actin. This gene is also expressed by fibrocytes in response to TGF-β and
other cytokines that promote tumor stromagenesis (8). Thus, fibrocytes can promote
tumorigenesis by becoming incorporated into the stroma.
Despite the appeal of this hypothesis, this model is flawed. The small number of circulating
fibrocytes likely limits their contribution to the tumor stroma. This observation has already
been demonstrated in liver and dermatologic diseases associated with fibrocytes (9).
Moreover, the tumor stroma has many other sources of activated fibroblasts (10). This
hypothesis also fails to consider other biologic functions connected to fibrocytes. For
example, fibrocytes contribute to innate immunity by the expression of antimicrobial factors
(11) and adaptive immunity by Ag presentation (12). In short, fibrocytes have numerous
functions that might be critical for tumor promotion. Furthermore, these functions may be
independent of their ability to be incorporated into the tumor stroma.
This report establishes a new biologic role for fibrocytes as regulators of cell migration. In
the process, we also provide experimental evidence that directly links fibrocytes to cancer
progression. In our model, circulating fibrocytes prompt an influx of Ly-6C+, Ly-6Glo
monocytes into the lung. This influx conditions the lung to make it more vulnerable to the
invasion of cancer cells. Our model is consistent with the observations of Kaplan and others
who have described the establishment of the premetastatic niche by Ly-6C+ monocytes (13).
We also show that this process is dependent on CCR2 and CCR5, adding to the preclinical
data that establish these chemokine receptors as potential therapeutic targets.
Materials and Methods
Mice and cell lines
C57BL/6J Ccr5−/− have been previously described (14); matrix metal-loproteinase 9
knockout mice (Mmp9−/−) were a gift from Dr. Lynn Matrisian. All other mouse strains
were purchased from The Jackson Laboratory (Bar Harbor, ME). All animals were housed
in pathogen-free conditions. Ccr5−/− × Mmp9−/− mice were produced by crossing F1
progeny of Ccr5−/− and Mmp9−/− mice.
All experiments were conducted using protocols approved by the Institutional Animal Care
and Use Committee of the University of North Carolina–Chapel Hill. B16-F10, CT26, and
Line 1 cell lines were purchased form American Type Culture Collection (Rockland, MD).
Cell lines were verified using short tandem repeat analysis.
In vivo experiments
Pulmonary mesenchymal cells (PMCs) were isolated as described previously (15).
Fibrocytes were separated from PMCs using CD45 Miltenyi beads (Bergisch Gladbach,
Germany) according to the manufacturer’s instructions. Immature dendritic cells were
cultured from bone marrow using GM-CSF (Invitrogen) and B cells were isolated from
splenocytes also using B220 beads.
Details for the melanoma metastasis model have been described previously (16). In brief, 1
× 105 fibrocytes in 200 μl PBS were injected via the tail vein. Twenty-four hours later, 7.5 ×
105 B16-F10 melanoma cells were injected. Mice were euthanized 14 d later, and metastases
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were counted after insufflation with Fekete’s destaining solution. Experiments using other
cell lines were performed in a similar manner. CT26 cells (1 × 105) were injected into
C57BL/6J mice and 2 × 105 Line 1 cells were injected into BALB/c mice. Visualization of
tumor nodules was enhanced by insufflation with 15% solution of India ink–PBS followed
by storage in Fekete’s solution.
Ex vivo experiments
The formation of enhanced GFP (EGFP) bone marrow chimeric mice has already been
described (17). In brief, wild type (WT) mice were irradiated with 950 rad and injected with
3 × 106 bone marrow cells from EGFP transgenic mice. Recipient mice were maintained for
8 wk prior to their use in these studies. Details for flow cytometry and PCR have been
described previously (18). Real-time PCR was performed on cDNA synthesized with M-
MLV reverse transcriptase (Invitrogen) and random hexamers. Transcript number was
measured with SYBR green and an ABI PRISM 7900 real-time RT-PCR system (Applied
Biosystems, Foster City, CA). The copy number was normalized against the absolute mRNA
amount as measured by Qubit Quantitation Platform (Invitrogen). Abs and primer sequences
are given in Supplemental Table I.
Western blotting was performed on FACS-sorted pulmonary cells as previously described
(18). The samples were run on a 10% SDS gel before being transferred to nitrocellulose.
Primary Abs were diluted to 1:1000, and secondary Abs were diluted to 1:10,000.
Cytospin slides were prepared from a single-cell suspension of CD11b+ pulmonary cells
isolated by immunomagnetic beads and resuspended in 0.5% BSA. After Wright–Giemsa
staining, differential counts were performed on 500 or more cells by an investigator
(H.W.v.D.) blinded to the treatment.
Statistics
Unless otherwise stated, data are presented as the mean of measurements taken from three or
more separate experiments. Statistical error for these means is presented as ± 1 SEM.
Confidence intervals were determined using a 60% trimmed mean. The p values were
determined by Mann–Whitney U test and values less than 0.05 were considered significant.
The Bonferroni correction was applied to experiments involving multiple comparisons.
Results
WT fibrocytes increase metastasis in Ccr5−/− mice
PMCs can be isolated by culturing a single-cell suspension from the lung and harvesting the
adherent cells in two to three weeks. The resultant cells increase metastasis in Ccr5−/− mice
when injected prior to the injection B16-F10 melanoma cells (17). This observation is not
limited to the B16-F10 cell line. As demonstrated in Fig. 1A, PMCs also increased
metastasis in WT mice when transferred prior to the i.v. injection of CT26 cells (12.4 ± 1.9
versus 96.8 ± 6.4; p < 0.001) or Line 1 cells (1.3 ± 0.4 versus 7.9 ± 2.1; p < 0.001).
PMCs can be separated by CD45 expression into CD45− fibroblasts and CD45+ fibrocytes.
We used this distinction to isolate fibrocytes with immunomagnetic beads (Fig. 1B). The
isolated cells expressed CD11b, CD13, and collagen, type 1, α 1 (Col1A1), consistent with a
fibrocyte phenotype (Fig. 1C). The purity of this isolate was 91% ± 3.0% based on Col1A1
expression. The hematopoietic lineage of these fibrocytes was then confirmed by creating
chimeric mice with EGFP transgenic bone marrow (Fig. 1C); 90.1 ± 0.2% of the CD45+
fibrocytes isolated from the chimeric mice expressed EGFP, indicating that these cells were
derived from bone marrow precursors.
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To determine whether fibrocytes were the subset of PMCs that mediated pulmonary
metastases, we transferred 1 × 105 fibrocytes into Ccr5−/− mice prior to the injection of the
B16-F10 cells. These mice developed an equivalent number of metastases (73 ± 2) as WT
mice injected with WT fibrocytes (85 ± 5) and WT mice that were not treated with
fibrocytes (69 ± 4; Fig. 2A). The size and distribution of the metastatic colonies were similar
with all three treatments; the only difference was the number of metastases (Supplemental
Fig. 1). All three of these groups had significantly more pulmonary metastases than
uninjected Ccr5−/− mice (49 ± 3; p < 0.01) or mice injected with Ccr5−/− fibrocytes (32 ± 5;
p < 0.001). CD45− fibroblasts, however, did not increase metastasis compared with
fibrocytes (72 ± 10 versus 113 ± 4; p < 0.002; Fig. 2B). Therefore, these data indicate that
the fraction of PMCs promoting lung metastases is the CD45+ fibrocyte fraction.
WT fibrocytes promote metastasis via MMP9
WT PMCs increase metastasis by inducing MMP9 (16). To determine whether fibrocytes
promote metastasis by an MMP9-dependent mechanism, we transferred WT fibrocytes into
Mmp9−/− mice. As hypothesized, pulmonary metastases were not increased in Mmp9−/−
mice as they were in Ccr5−/− mice (43 ± 2 versus 96 ± 6; p < 0.01; Fig. 2C, Supplemental
Fig. 1).
These data suggest that CCR5 and MMP9 are part of the same prometastatic pathway. We
looked for the potential additive benefit of inhibiting both CCR5 and MMP9 by crossing
Mmp9−/− mice with Ccr5−/− mice. As shown in Fig. 2D, metastasis in the double knockout
was not inhibited more than either Ccr5−/− or Mmp9−/− mice (48 ± 2 versus 51 ± 3 versus 37
± 3; p = NS). All three of these groups had fewer metastases than did the control WT mice
(72 ± 6; p < 0.05). Therefore, our data indicated that fibrocytes were critical to the
promotion of pulmonary metastases and that this process required MMP9 and CCR5, which
function via a cis-mediated mechanism.
WT fibrocytes recruit Ly-6C+, Ly-6Glow monocytic cells
Next, we sought the mechanism by which fibrocytes increase pulmonary metastases.
Previous work suggested that WT PMCs induced the migration of CD11b+ cells into the
lung. We reexamined this finding by injecting EGFP+ fibrocytes from WT and Ccr5−/− mice
into Ccr5−/− animals. This design allowed us to exclude the injected fibrocytes by gating on
the EGFP− cells. As before, WT EGFP+ fibrocytes induced a statistically significant
increase in CD11b+ cells in the lung (p < 0.02; Fig. 3A). No such increase was found in
CD11b− cells after the injection of fibrocytes. Injection of Ccr5−/− fibrocytes failed to
increase CD11b+ or CD11b− cells.
Flow cytometry was then used to identify the following CD11b+ cells: monocytes,
macrophages, dendritic cells, granulocytic (Gr-1Hi) myeloid derived suppressor cells
(MDSCs), and monocytic (Gr-1Int) MDSCs (Fig. 3B). All other CD11b+ cells were labeled
as myeloid cells, not otherwise specified (NOS). Using this approach, the monocytic MDSC
was the only population significantly increased by WT but not Ccr5−/− fibrocytes (p < 0.02;
Fig. 3C).
Because Gr-1 is a nonspecific marker for myeloid cells, the Gr-1Int population was analyzed
further with Ly-6C and Ly-6G Abs. As shown in Fig. 3D, WT fibrocytes did not increase
the percentage of Ly-6G+ cells (13.6 ± 1.1 versus 13.3 ± 2.5%; p = NS). However, Ly-6C+,
Ly-6Glow cells were significantly increased (17.0 ± 2.0 versus 11.7 ± 2.2%; p < 0.01) after
the injection of WT fibrocytes. These flow cytometry results were corroborated by
performing differential counts on cytospin preparations of the CD11b+ cells. Monocytes
were more prevalent in mice injected with WT fibrocytes compared with the controls (33.2
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± 1.3% versus 25.2 ± 3.0% versus 19.6 ± 1.1%; p < 0.05; Fig. 3E). From these data, we
concluded that WT fibrocytes enhanced the recruitment of Ly-6C+, Ly-6Glow monocytes
into the lung.
Ly-6C+, Ly-6Glow monocytic cells are consistent with premetastatic monocytes
The premetastatic niche is formed by monocytes characterized by the expression of CD11b,
Ly-6C, CD45, CD117, and Itga4 (19). As demonstrated above, fibrocytes recruited
monocytes that expressed CD11b and Ly-6C. These monocytes also expressed CD45,
CD117, but not CD11c (Fig. 4A). The presence of Itga4 but not Mmp9 was shown by
Western blotting applied to monocytes isolated from the lungs of fibrocyte-injected mice
(Fig. 4B).
The defining property of premetastatic monocytes is their capacity to promote metastasis.
This ability was tested by isolating Ly-6C+ cells from Ccr5−/− mice injected with WT
fibrocytes and then transferring 2 × 105 of these cells into mice that had not received
fibrocytes (Fig. 4C). As shown in Fig. 4D, fibrocyte-recruited Ly-6C+ monocytes
significantly increased metastasis in Ccr5−/− mice whereas B cells and immature dendritic
cells did not (90 ± 8 versus 26 ± 2 and 31 ± 6 respectively; p < 0.01).
The importance of Ly-6C+ monocytes in this model was further strengthened by depleting
the Ly-6G++ cells. These cells could be depleted from the lung with the Ly-6G Ab or with
the Gr-1 Ab (18) (Fig. 4E, 4F). Depletion of these cells with either Ab had no effect on the
fibrocytes’ ability to increase metastasis (Fig. 4G). Therefore, the promotion of metastasis
by fibrocytes was not dependent on the recruitment of Ly-6G++ cells. Instead, the
prometastatic effect of fibrocytes was limited to their influence on the population of Ly-6C+
myeloid cells.
Ly-6C+ cells are recruited by CCL2-CCR2 axis
Next, we evaluated the fibrocytes’ dependence on Ly-6C+ cells in the promotion of lung
metastasis. Ab depletion of the Ly-6C+ cells is not possible because of the ubiquitous
expression of this protein. However, the migration of Ly-6C+ monocytes can be inhibited by
blocking CCR2. In the Ccr2−/− mouse, injection of WT fibrocytes did not increase the
number of Ly-6C+ cells in the lung (5.8 ± 0.6 × 105 versus 7.1 ± 2.4 × 105 cells; p = NS;
Fig. 5A). The only significant increase in cell number came after the injection of WT
fibrocytes into Ccr5−/− mice (17.3 ± 0.2 × 105 cells; p < 0.05). The percentage of monocytes
was also not increased in the Ccr2−/− mice as measured by differential counts of CD11b+
cells recognized on cytospin slides (22.7 ± 0.7% versus 22.7 ± 2.2%; Fig. 5B).
If the recruitment of Ly-6C+ myeloid cells was critical to the ability of fibrocytes to enhance
metastasis, then fibrocytes should not increase metastasis in the Ccr2−/− mouse. As
expected, WT, Ccr2−/−, or Ccr5−/− fibrocytes did not increase in metastasis in Ccr2−/− mice
(Fig. 5C). Once again, the size and distribution of the metastatic colonies was substantially
different (Supplemental Fig. 2). These results confirmed the requisite role of the migration
of CCR2-expressing Ly-6C+ cells in this process.
The predominant ligand for CCR2 is CCL2. In our model, CCL2 could be generated by
migrating fibrocytes or by the surrounding pulmonary stroma. To answer this question, Ccl2
was measured in the lung of Ccr5−/− mice before and after injection with WT and Ccl2−/−
fibrocytes. Using real-time PCR, WT and Ccl2−/− fibrocytes increased Ccl2 expression by
2.07 ± 0.05-fold and 2.78 ± 0.36-fold, respectively (p = NS). Both were significantly greater
than baseline expression of Ccl2 (1.0 ± 0.06; p < 0.05). These results suggested that Ccl2
induction by fibrocytes was not cell intrinsic because fibrocytes lacking Ccl2 induced
similar levels of the chemokine in the lung.
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The importance of fibrocyte-generated CCL2 on metastasis was tested by injecting Ccr5−/−
mice with WT and Ccl2−/− fibrocytes. As shown in Fig. 5D, metastasis was increased in
Ccr5−/− mice by the injection of WT and Ccl2 −/− fibrocytes compared with control (75 ±
12, 76 ± 6, 45 ± 6; p < 0.05). In contrast, WT and Ccl2−/− fibrocytes did not increase
metastasis in Ccl2−/− mice (52 ± 6, 53 ± 13) compared with Ccl2−/− mice that had not
received fibrocytes (51 ± 7). All three groups had fewer metastases than did Ccr5−/− mice
injected with WT fibrocytes (96 ± 5; p ≤ 0.02). These results indicate that the injection of
fibrocytes mediates the expression of CCL2 by pulmonary cells.
Discussion
By adoptively transferring WT fibrocytes into Ccr5−/− mice, this report provides
confirmation that fibrocytes promote lung metastasis. We intentionally injected fibrocytes
before injecting tumor cells. This “premetastatic” model allowed us to study changes
induced by the fibrocytes that were not influenced by local tumor. As a result, we were able
to show that fibrocytes promoted metastasis by recruiting Ly-6C+ monocytes. Therefore, our
data suggest a new function for fibrocytes as regulators of cellular migration.
Fibrocytes have been described in precancerous lesions and in the peritumoral stroma (20,
21). Tumor stroma, however, has significantly reduced numbers of fibrocytes but increased
numbers of myofibroblasts. These observational studies assumed the increase in
myofibroblasts was due to the transition of fibrocytes to activated fibroblasts. However,
these studies were correlative and ignored the predominant sources of tumor-associated
fibroblasts. Pericytes, adipocytes, and epithelial cells are all capable of trans-differentiating
into stromal cells (22). Bone marrow mesenchymal cells also contribute to the myofibroblast
pool (23). Given the large number of cells capable of generating stromal cells, the overall
contribution of a small population of migrating fibrocytes could be considered
inconsequential. Although the transition from fibrocyte to fibroblast is well documented,
incorporation into the stroma might not be their primary mechanism of promoting disease.
Our model would add additional complexity to the interpretations of data from these older
studies by demonstrating that fibrocytes recruit immunosuppressive myeloid cells to the
lung. Such a function would distinguish these cells from other fibroblast precursors.
Premetastatic niches are clusters of bone marrow–derived cells that facilitate the invasion
and survival of circulating tumor cells (24). Initially described by Kaplan et al. (13) and later
confirmed by several additional investigators, the cells of this niche express CD11b+ (25),
Gr-1+ (26), Itga4 (13), CD133, CD34, cKit (CD117), and VLA4 (19). This description is
consistent with the Ly-6C+ monocytes recruited by fibrocytes described in the current work.
Furthermore, adoptive transfer of these cells established their functional capacity as
premetastatic promoters of metastasis.
Experimental evidence for the creation of premetastatic niches is growing. Premetastatic
infiltration by monocytes has been described in models of pancreatic (27) and breast cancer
(28). Mechanisms underlying the creation of such niches are also beginning to emerge (29),
(25), (30), (31). The predominant mechanism of monocyte recruitment in this study was the
induction of CCL2. This chemokine has been associated with poorer outcomes in several
cancers, including myeloma, breast cancer, and prostate cancer (30). The receptor, CCR2,
promotes invasion of myeloid cells after treatment, which creates a greater risk of relapse
(32). Polymorphisms that increase CCR2 expression are associated with a greater risk of
death in prostate (33) and gastric cancer (34). In the murine metastasis models, Ccl2 has
been implicated in the influx of Gr-1+ monocytes in pulmonary metastasis, but not primary
mammary tumors in mice. Blockade of Ccl2 inhibits these inflammatory monocytes and
prolongs survival (35).
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CCL2 can also contribute to the promotion of metastasis by inducing the expression of
MMP9 (36). This metalloproteinase is required for the formation of premetastatic niche (37)
and for the induction of angiogenesis (38). Our model was also dependent on the expression
of MMP9. Together, these signals can establish a positive feedback loop. MMP9 contributes
to the recruitment of additional monocytes in a cathepsin-L–dependent manner (39), and
CCL2 recruits additional fibrocytes (40). These mechanisms would explain why small
numbers of fibrocytes have such profound effects on metastasis.
These data could help to clarify aspects of tumor biology that are poorly understood. For
example, several studies have suggested that surgery could have prometastatic effects (41).
Peak mobilization of fibrocytes occurs between 3 and 7 d after wound formation (42). These
circulating fibrocytes could subsequently condition the stroma for cancer cells emigrating
from stem cell niches in the bone marrow. Although this mechanism has not been studied in
cancer patients, a similar phenomenon has been documented for endothelial progenitor cells
(43).
Our data suggest means of interrupting this pathway, which could create a new means of
preventing metastasis. Our work has focused on decreasing fibrocyte migration through the
chemokine pathways. Fibrocyte migration has also been decreased by inhibition of MTOR
(44), the angiotensin II type 1 receptor (45), Kcs3.1K+ channels (46) or CXCR4 (47).
Inhibition of fibrocytes and monocytes might also be possible through the development of
dual CCR5/CCR2 inhibitors (48).
In summary, we have presented a mechanism by which fibrocytes can prepare the
pulmonary stroma for metastasis by recruiting Ly-6C+, Ly-6Glow monocytes through the
induction of CCL2. The interactions among fibrocytes, monocytes, and cancer cells depend
on CCR5, CCR2, and MMP9. This work has implications for conditions that promote
fibrocyte migration, such as surgery, and it provides a rationale for novel combinations of
currently existing therapeutics.
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Characterization and isolation of fibrocytes. (A) Injection of WT pulmonary mesenchymal
cells increases metastases with CT26 and Line 1 tumor cells. The graph shows the number
of metastatic foci in BALB/c mice injected with 4 × 105 pulmonary mesenchymal cells
(PMCs; striped bars) compared with PBS-injected controls (solid bars). The graph on the
left demonstrates a 7.8-fold increase in metastasis after injection with 1 × 105 CT26 cells (n
= 20). The graph on the right shows a 6.2-fold increase after an injection with 2 × 105 Line 1
cells (n = 22). (B) CD45+ fibrocytes can be isolated using immunomagnetic bead selection.
Pulmonary mesenchymal cells were isolated from minced lung cultures as described. These
cells were incubated with CD45 immunomagnetic beads and selected with Miltenyi
magnetic columns. Representative dot plots are shown for cells prior to selection (left),
CD45 selected cells (center), and flow through cells (right; n = 4). (C) CD45+ PMCs are
phenotypically consistent with fibrocytes. Flow cytometry was performed on PMCs for the
indicated markers. Representative histograms are shown for CD45+ cells (solid gray) and
isotype control (black line). (D) CD45+ fibrocytes originate in the bone marrow. WT bone
marrow chimeric mice were formed by injecting 3 × 106 bone marrow cells from EGFP
transgenic mice into irradiated WT mice. Six to eight weeks later, the lungs were harvested
and PMCs were isolated using the standard 2-wk protocol. The cells were then assessed by
flow cytometry. The dot plot on the left shows PMCs characterized by forward scatter and
CD45 expression. The histogram on the top right shows the percentage of EGFP+ cells taken
from the CD45+ PMCs (R2). The histogram on the bottom shows EGFP+ cells taken from
the CD45− PMCs (R3). The unfilled black line is EGFP expression for WT mice injected
with WT (non-EGFP) marrow (n = 8).
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WT CD45+ fibrocytes increased metastasis in Ccr5−/− mice via Mmp9. (A) Bar graphs
depicting the number of metastases in WT and Ccr5−/− (R5) mice following the injection of
1 × 105 WT or Ccr5−/− fibrocytes (Fcyte); 7.5 × 105 B16-F10 melanoma cells were injected
i.v. 24 h after fibrocytes. Metastases were counted 2 wk later (n = 50). (B) Bar graphs
depicting metastasis in Ccr5−/− mice (left) and Ccr5−/− mice following injection with either
1 × 105 WT fibroblasts (Fblasts) or fibrocytes (Fcytes; n = 26). (C) Bar graphs showing
metastasis in Ccr5−/− and Mmp9−/− (M9) mice following injection with WT or Mmp9−/−
fibrocytes (n = 92). (D) Bar graph showing metastasis in mice without fibrocyte injection.
WT mice (solid black) had significantly more metastases than Ccr5−/−, Mmp9−/− or the
double knockout Mmp9−/− × Ccr5−/− (checkerboard; n = 47).
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WT fibrocytes recruited Ly-6+, Ly-6Glo cells in Ccr5−/− mice. (A) CD11b+ cells were
increased in Ccr5−/− mice 24 h after the injection of WT EGFP+ fibrocytes. Dot plot shows
gating strategy for calculating CD11b+ cell number. The bar graph shows the fold increases
of CD11b+ (black bars) and CD11b− (striped; n = 22). (B) Gating strategy for the
identification of CD11b+ cells after injection with WT fibrocytes. The top row of dot plots
were stained with isotype controls; the bottom row plots were stained with CD115, F4/80,
CD11c, and Gr-1. (C) Bar graphs depicting fold induction of cell subpopulations following
injection with Ccr5−/− (striped) or WT (solid) fibrocytes. Significant fold induction was seen
in only monocytic MDSCs (n = 20). (D) Dot plots from Ccr5−/− mice following the injection
of Ccr5−/− (center) or WT (right) fibrocytes. Ly-6C+, Ly-6G− were significantly increased
after injection of WT cells. (E) Differential percentages of CD11b+ cells as detected on
cytospin preparations. All differentials performed on CD11b+ cells from Ccr5−/− mice after
injection with WT fibrocytes (left), Ccr5−/− fibrocytes (center) or no fibrocytes (right; n =
24).
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Ly-6C+, Ly-6Glo cells recruited by fibrocytes promoted metastasis. (A) Flow cytometric
analysis of Ly-6Glo, Ly-6C+ cells. Gating strategy is on the left; histograms for CD45,
CD11c, and CD117 are given on the right (n = 5). (B) Western blot analysis of Ly-6Glo,
Ly-6C+ cells isolated from Ccr5−/− mice by flow sorting following injection with WT
fibrocytes. (C) Experimental schema for defining function of Ly-6C+ monocytes. Ly-6C+
cells were isolated from Ccr5−/−(R5) mice 24 h after fibrocyte injection and transferred into
R5 mice. Tumor cells were injected within 4 h of monocyte injection. (D) Bar graph shows
metastasis in Ccr5−/− mice injected with Ccr5−/− fibrocytes or 5 × 106 WT B cells, 1 × 106
WT immature dendritic cells (iDCs), 2 × 105 WT Ly-6C+ monocytes, or WT fibrocytes (n =
42). (E) Experimental schema for the depletion Gr-1 cells. Gr-1 or Ly-6G Ab was given on
days −2,, 0, and 2 in relationship to the i.v. injection of B16 F10 cells (day zero). Fibrocytes
(1 × 105) were given on day −1; flow cytometry was performed on day 3. (F) Representative
dot plots of pulmonary cells from mice treated with either Gr-1 or Ly-6G Ab. The graph on
the left includes all cells (excluding debris by FSC/SSC); the graph on the right represents
only CD11b+ cells. (G) Bar graph displaying the number of metastasis in mice treated with
Gr-1 (n = 15) or Ly-6G (n = 31) Ab. Untreated Ccr5−/− mice (black) had statistically fewer
metastases than all other groups. There were no significant differences in Ccr5−/− mice
injected with WT fibrocytes.
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Fibrocytes recruited premetastatic monocytes via CCR2. (A) Bar graphs depicting total
number of cells for each subpopulation following the injection with Ccr5−/− (R5), Ccr2−/−
(R2), or WT fibrocytes. Significant increase was seen in monocytic MDSCs only. (B) Pie
graphs showing differential percentages of CD11b+ cells as detected on cytospin
preparations. All differentials performed on CD11b+ cells from Ccr2−/− mice after injection
with WT (top) or Ccr5−/− fibrocytes (bottom). (C) Bar graph depicting fold increase in Ccl2
mRNA expression in Ccr5−/− mice following injection with WT, Ccl2−/−, or Ccr5−/−
fibrocytes (n = 16). (D) Bar graph representing lung metastasis in Ccr5−/− or Ccr2−/− mice
injected with WT, Ccr2−/−, or Ccr5−/− fibrocytes (n = 72). (E) Bar graph showing the
number of metastases in Ccr5−/− or Ccl2−/− after the injection of WT or Ccl2−/− fibrocytes
(Fcyte; n = 70).
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